Anthony Devincentis, MD
Glaucoma Specialist · Syracuse, NYNPI 1538362058
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,067 of the $2,442 with a category attached, or 84.6%. It is spread thinly across 16 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for glaucoma specialist clinicians in NY, where the typical reported total is $2,507.
Across 114 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$389
- Welch Allyn$375
- AbbVie$370
- Oyster Point Pharma, Inc.$324
- Novartis$258
- Sun Pharmaceutical Industries Inc.$129
- plus $597 from 10 others
Across 3 payments — averaging $1292.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Welch Allyn$4K
What the payments were for
- Speaking & faculty fees$37515%
- Food & beverage$2,06785%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 26 | $389 |
| Welch Allyn | 1 | $375 |
| AbbVie(2 entities) | 20 | $370 |
| Oyster Point Pharma, Inc. | 16 | $324 |
| Novartis | 18 | $258 |
| Sun Pharmaceutical Industries Inc. | 7 | $129 |
| Bausch & Lomb Americas Inc. | 7 | $119 |
| Sight Sciences, Inc. | 2 | $114 |
| Amgen | 4 | $100 |
| Thea Pharma Inc. | 4 | $83 |
| Tarsus Pharmaceuticals, Inc. | 2 | $58 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $46 |
| Kala Pharmaceuticals, Inc. | 2 | $35 |
| Harrow Eye, LLC | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Digital MacroView Otoscope$375
- PanOptic Ophthalmoscope$375
- iExaminer Image Reader$375
How this compares
$2,442 in reported general payments places this provider in the 45th percentile of 35 glaucoma specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 713 | $424,526 |
| Travoprost | 528 | $135,046 |
| RhopressaNetarsudil Mesylate | 195 | $132,702 |
| Brimonidine Tartrate | 752 | $81,699 |
| Brinzolamide | 296 | $79,695 |
| Alphagan PBrimonidine Tartrate | 142 | $65,454 |
| CombiganBrimonidine Tartrate/Timolol | 146 | $64,723 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 209 | $50,142 |
| RocklatanNetarsudil Mesylat/Latanoprost | 62 | $45,128 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 99 | $42,436 |
| Bimatoprost | 238 | $39,712 |
| Bromfenac Sodium | 160 | $32,709 |
| Timolol Maleate | 489 | $28,212 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,249 | $27,368 |
| AzoptBrinzolamide | 34 | $26,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan | $370 | $554,7031,001 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $12 | $177,830257 claims |
| AlconSimbrinza, Azopt | $389 | $68,903133 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa, Lotemax Sm | $46 | $39,677138 claims |
| NovartisIlevro | $258 | $21,12740 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $119 | $8,66512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 35 glaucoma specialist providers in New York.
Other glaucoma specialist in Syracuse
- Janet SerleNew York$103K
- Sarah VantasselNew York$76K
- Jonathan SchulhofBrooklyn$73K
- Sonya DharNew York$19K
- Jacqueline LenociCommack$13K
- Tak Yee Tania TaiBrooklyn$11K
- Leah UmfreyAlbany$6K
- Smitha VoletiYonkers$5K
- Yvonne OkakaNew York$5K
- Brian KrawitzBronx$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.